123 related articles for article (PubMed ID: 34656230)
1. Overexpression of Hepatocyte growth factor and its soluble receptor (s-cMet) in the serum of patients with different grades of meningioma.
Mashayekhi F; Sasani ST; Saberi A; Salehi Z
J Clin Neurosci; 2021 Nov; 93():1-5. PubMed ID: 34656230
[TBL] [Abstract][Full Text] [Related]
2. Soluble c-Met expression in the peritoneal fluid and serum of patients with different stages of endometriosis.
KhoshdelRad N; Salehi Z; Mashayekhi F; Abbasi O; Mirzajani E
Arch Gynecol Obstet; 2014 May; 289(5):1107-12. PubMed ID: 24213016
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas.
Martínez-Rumayor A; Arrieta O; Guevara P; Escobar E; Rembao D; Salina C; Sotelo J
Cancer Lett; 2004 Sep; 213(1):117-24. PubMed ID: 15312691
[TBL] [Abstract][Full Text] [Related]
4. Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma.
Mashayekhi F; Saberi A; Mashayekhi S
Clin Neurol Neurosurg; 2018 Jul; 170():84-87. PubMed ID: 29753168
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma.
Arrieta O; Garcia E; Guevara P; Garcia-Navarrete R; Ondarza R; Rembao D; Sotelo J
Cancer; 2002 Jun; 94(12):3210-8. PubMed ID: 12115353
[TBL] [Abstract][Full Text] [Related]
6. Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy.
Serilmez M; Özgür E; Karaman S; Gezer U; Duranyıldız D
Cancer Biomark; 2019; 25(2):177-184. PubMed ID: 31104010
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor and soluble cMet levels in plasma are prognostic biomarkers of mortality in patients with severe acute kidney injury.
Li L; An JN; Lee J; Shin DJ; Zhu SM; Kim JH; Kim DK; Ryu DR; Kim S; Lee JP
Kidney Res Clin Pract; 2021 Dec; 40(4):596-610. PubMed ID: 34510856
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma.
Ramirez R; Hsu D; Patel A; Fenton C; Dinauer C; Tuttle RM; Francis GL
Clin Endocrinol (Oxf); 2000 Nov; 53(5):635-44. PubMed ID: 11106926
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression.
Noguchi E; Saito N; Kobayashi M; Kameoka S
Mol Med Rep; 2015 May; 11(5):3423-31. PubMed ID: 25592281
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.
Lamszus K; Lengler U; Schmidt NO; Stavrou D; Ergün S; Westphal M
Neurosurgery; 2000 Apr; 46(4):938-47; discussion 947-8. PubMed ID: 10764269
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
Klotz DM; Link T; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Dec; 15(12):3626-3638. PubMed ID: 33738970
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Fujikawa H; Matsushita K; Okugawa Y; Inoue Y; Uchida K; Mohri Y; Kusunoki M
Int J Oncol; 2012 Feb; 40(2):583-91. PubMed ID: 21922134
[TBL] [Abstract][Full Text] [Related]
14. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.
Dilwali S; Roberts D; Stankovic KM
Cancer Biol Ther; 2015; 16(1):170-5. PubMed ID: 25692621
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.
Kim H; Youk J; Yang Y; Kim TY; Min A; Ham HS; Cho S; Lee KH; Keam B; Han SW; Oh DY; Ryu HS; Han W; Park IA; Kim TY; Noh DY; Im SA
J Cancer Res Clin Oncol; 2016 Mar; 142(3):707-14. PubMed ID: 26577828
[TBL] [Abstract][Full Text] [Related]
16. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus.
Shinoda K; Ishida S; Kawashima S; Wakabayashi T; Matsuzaki T; Takayama M; Shinmura K; Yamada M
Br J Ophthalmol; 1999 Jul; 83(7):834-7. PubMed ID: 10381671
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
Tanimoto S; Fukumori T; El-Moula G; Shiirevnyamba A; Kinouchi S; Koizumi T; Nakanishi R; Yamamoto Y; Taue R; Yamaguchi K; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Takahashi M; Kanayama HO
J Med Invest; 2008 Feb; 55(1-2):106-11. PubMed ID: 18319552
[TBL] [Abstract][Full Text] [Related]
19. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
Kim KH; Kim H
Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal fluid and serum levels of hepatocyte growth factor may predict the activity of endometriosis.
Khan KN; Masuzaki H; Fujishita A; Kitajima M; Hiraki K; Miura S; Sekine I; Ishimaru T
Acta Obstet Gynecol Scand; 2006; 85(4):458-66. PubMed ID: 16612709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
